Research programme: influenza DNA vaccines - Inovio

Drug Profile

Research programme: influenza DNA vaccines - Inovio

Alternative Names: GLS-3700; H7N9 influenza DNA vaccine - Inovio; Influenza A virus H7N9 DNA vaccine - Inovio; Pandemic influenza DNA vaccine - Inovio; Prophylactic pre-pandemic influenza DNA vaccine cocktail (VGX-3500) - Inovio; Seasonal influenza DNA vaccine - Inovio; SynCon™ universal flu vaccine - Inovio; Universal Flu DNA Vaccine - Inovio; Universal Influenza DNA Vaccine - Inovio; VGX 3500; VGX-3500 (H5 + H1) DNA vaccine; VGX-3500X

Latest Information Update: 19 Sep 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Inovio Biomedical Corporation; VGX International
  • Developer Inovio Pharmaceuticals
  • Class Influenza A virus H1N1 vaccines; Influenza A virus H5N1 vaccines; Influenza A virus H7N9 vaccines; Influenza virus DNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Influenza A virus H1N1 subtype; Influenza A virus H5N1 subtype; Influenza A virus H7N9 subtype; Influenza virus infections

Most Recent Events

  • 09 Jul 2014 Influenza DNA vaccines is available for licensing as of 09 Jul 2014 (http://www.inovio.com/products/infectious-disease-vaccines/influenza/pandemic/)
  • 08 Jul 2013 Pharmacodynamics data from a preclinical trial in Influenza-A virus H7N9 subtype (prevention) released by Inovio Pharmaceuticals
  • 20 Jun 2013 Preclinical trials of VGX 3500 in Influenza-A virus H1N1 subtype (prevention) in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top